ArticleFrontiers in oncology2025
Diagnostic value of magnetic resonance imaging for malignant ovarian tumors mis-subclassified by the ultrasound-based ADNEX model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The use of MRI in the diagnosis of ovarian cancer.Frontiers in medicine · 2026Review
- Benign serous cystadenofibroma with multimodal imaging suggestive of malignancy in a symptomatic postmenopausal patient.Przeglad menopauzalny = Menopause review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Accurately predicting metastatic cancer to the adnexa, stage I and advanced ovarian cancer before surgery is crucial. The ADNEX model, based on ultrasound, is currently the only prediction model that can differentiate between these types. This study aims to analyze MRI features and diagnostic value in malignant ovarian tumors mis-subclassified by the ADNEX model, considering their diverse histopathologic types. Methods: From January 2018 to September 2022, 164 patients with pathologically confirmed ovarian malignancies were selected from those who were examined by ultrasound. The clinical and MRI characteristics of 51 patients mis-subclassified by the ADNEX model were compared with histopathological types. Results: A total of 30 were confirmed with primary ovarian cancer (5 with HGSOC, 14 with CCC, 2 with EC, 4 with MC, 2 with GCT, 1 with YST, 1 with immature teratoma, and 1 with dysgerminoma). There were 21 patients who had metastatic ovarian tumors (10 with colorectal cancer, 4 with gastric cancer, 2 with uterine cervical cancer, 3 with endometrial cancer, 1 with breast cancer, and 1 with LAMN). The only significant difference between the two groups was in CEA. The mean diameters of the primary and metastatic ovarian tumors were 10.29 cm (range: 3.61 cm-26.02 cm) and 8.58 cm (range: 3.10 cm-20.30 cm), respectively. A total of 42 masses were lobulated (82.35%, 42/51), and 26 masses were solid-cystic (26/51, 50.98%). There was a significant difference between CCC and other tumors, with mean ADC values of 1.01 × 10 Conclusions: DWI signal, ADC value, degree of enhancement, and characteristic components within the mass on MRI can provide supplementary information for malignant ovarian tumors mis-subclassified by the ADNEX model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.